Supriya Lifescience quarterly results and financials

Supriya Lifescience (SUPRIYA)₹631.25−3.03%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Supriya Lifescience reported sales of ₹276 Cr, up 50.7% from Mar 2025, and net profit of ₹74.01 Cr, up 48.1% year on year. For the year to Mar 2026, sales were ₹826 Cr and net profit ₹209 Cr.

Sales (Mar 2026): ₹276 Cr
Net profit (Mar 2026): ₹74.01 Cr
Sales (FY Mar 2026): ₹826 Cr
Net profit (FY Mar 2026): ₹209 Cr
EPS (Mar 2026): ₹9.23
Borrowings (Mar 2026): ₹4.99 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Supriya Lifescience quarterly results

₹ crore unless stated; each column is a quarter.

Supriya Lifescience Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	132	140	140	158	160	166	186	183	145	199	205	276
Expenses	87.74	108	98.66	103	97.65	101	120	117	92.64	127	134	178
Operating Profit	43.97	31.93	40.92	55.90	62.90	64.93	65.90	67.94	51.95	72.86	71.94	97.81
OPM %	34.0%	23.0%	30.0%	35.0%	39.0%	39.0%	36.0%	37.0%	36.0%	36.0%	35.0%	35.0%
Other Income	2.99	1.99	2.99	1.99	1.99	2.99	1.99	2.99	2.99	2.99	1.99	2.99
Interest	1.01	0.00	0.00	0.99	0.00	0.00	0.99	0.00	1.01	0.00	0.00	0.00
Depreciation	4.01	4.01	4.02	4.01	5.02	5.02	5.01	6.02	6.02	7.02	7.03	8.03
Profit before tax	43.04	29.99	40.02	52.99	60.07	62.01	63.03	63.99	47.04	67.99	66.99	91.98
Tax %	32.9%	20.0%	26.0%	31.0%	25.0%	25.9%	24.9%	21.0%	26.9%	25.9%	26.0%	18.9%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	28.99	23.99	30.02	36.98	45.01	45.98	46.98	49.96	34.99	49.99	49.98	74.01
EPS (Rs)	3.55	2.98	3.71	4.60	5.56	5.74	5.82	6.27	4.33	6.28	6.18	9.23

Supriya Lifescience profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Supriya Lifescience Profit and loss
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	184	212	277	311	390	528	460	568	694	826	826
Expenses	166	191	212	212	217	315	331	393	434	532	531
Operating Profit	16.98	21.96	64.92	97.89	173	214	129	176	261	293	295
OPM %	9.0%	10.0%	23.0%	32.0%	44.0%	40.0%	28.0%	31.0%	37.0%	36.0%	35.7%
Other Income	6.99	8.99	7.99	10.97	4.99	7.98	8.98	10.98	9.99	10.98	10.96
Interest	12.01	10.99	9.99	7.01	4.01	4.01	2.99	4.99	1.99	1.99	1.01
Depreciation	5.02	5.02	5.02	6.02	7.02	10.03	12.03	16.06	20.07	28.11	28.10
Profit before tax	8.01	14.02	57.03	95.98	167	207	123	166	248	275	274
Tax %	29.9%	39.9%	30.9%	23.9%	26.0%	26.9%	26.9%	28.0%	24.0%	23.9%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	6.01	9.01	39.02	73.05	124	152	90.06	119	188	209	209
EPS (Rs)	3.88	5.97	26.95	50.14	16.91	18.87	11.19	14.82	23.36	26.00	26.02
Dividend payout %	0.0%	0.0%	0.0%	20.1%	3.0%	3.0%	5.0%	5.0%	4.0%	4.0%	—

Supriya Lifescience balance sheet

₹ crore, at each year end.

Supriya Lifescience Balance sheet
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	14.96	14.97	14.97	14.96	14.98	15.98	15.96	15.97	15.98	15.96
Reserves	30.91	39.92	78.80	134	253	598	681	797	979	1,179
Borrowings	140	130	89.98	81.91	71.97	26.98	21.99	4.99	4.99	4.99
Other Liabilities	54.74	59.71	68.75	104	105	91.56	98.21	101	110	154
Total Liabilities	241	245	253	335	444	733	818	919	1,109	1,354
Fixed Assets	88.88	90.90	84.88	98.83	99.83	190	262	309	452	688
CWIP	35.87	33.89	34.88	39.88	78.82	42.90	67.83	149	148	35.92
Investments	0.00	0.00	0.00	0.00	0.00	0.00	24.89	63.78	62.74	98.69
Other Assets	117	120	133	196	266	500	465	398	447	532
Inventories	38.10	32.08	31.08	49.17	72.21	92.28	116	85.26	118	160
Trade receivables	49.95	52.88	59.86	51.89	73.82	115	84.88	112	134	219
Cash & equivalents	6.02	3.01	2.01	75.18	89.27	229	159	75.18	79.24	79.19
Total Assets	241	245	253	335	444	733	818	919	1,109	1,354

Supriya Lifescience cash flow

₹ crore, for each year.

Supriya Lifescience Cash flow
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from operating activity	26.88	27.91	48.80	117	75.75	48.83	63.78	113	164
Cash from investing activity	−27.06	−5.01	5.01	−25.08	−47.13	−60.15	−124	−175	−152
Cash from financing activity	−2.01	−20.01	−50.01	−29.03	−15.02	150	−10.01	−22.02	−8.01
Net cash flow	−1.99	2.99	3.99	61.87	14.97	139	−69.89	−82.82	3.99
Capex	9.98	4.99	6.99	24.95	47.94	59.93	108	146	162
Free cash flow	0.00	23.04	54.11	92.08	29.06	−11.03	−44.05	−32.05	2.01
CFO / OP %	158.0%	141.0%	97.0%	146.0%	61.0%	51.0%	73.0%	86.0%	86.0%

Supriya Lifescience ratios

Working-capital days and returns, by year.

Supriya Lifescience Ratios
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	98	91	78	59	68	78	66	70	69	96
Inventory days	112	84	76	129	205	171	233	139	204	228
Days payable	122	113	111	131	146	92	131	99	130	160
Cash conversion cycle	91	64	45	61	130	160	171	114	146	167
Working capital days	−69	−50	−5	−40	28	117	168	157	144	147
ROCE %	—	14.1%	37.1%	50.1%	60.1%	43.1%	19.1%	22.1%	27.0%	25.1%

Supriya Lifescience: frequently asked questions

What are the latest quarterly results of Supriya Lifescience?

For the Mar 2026 quarter, Supriya Lifescience reported sales of ₹276 Cr, up 50.7% year on year and net profit of ₹74.01 Cr, up 48.1% year on year. The operating margin was 35.0%.

What is the annual revenue of Supriya Lifescience?

Supriya Lifescience's sales for the year to Mar 2026 were ₹826 Cr; over the last twelve months they were ₹826 Cr.

What is the net profit of Supriya Lifescience?

Net profit for the year to Mar 2026 was ₹209 Cr, and ₹209 Cr over the last twelve months. Earnings per share over the same trailing period were ₹26.02.

How much debt does Supriya Lifescience have?

Supriya Lifescience reported borrowings of ₹4.99 Cr at Mar 2026, against cash and equivalents of ₹79.19 Cr.

What is the free cash flow of Supriya Lifescience?

Cash from operations was ₹164 Cr in the year to Mar 2025; after capital spending, free cash flow was ₹2.01 Cr.

Loading…